Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 9/20 | 0.83 |
| ▸ | CCNC | P24863 | 1/20 | 0.83 |
| ▸ | CDK8 | P49336 | 1/20 | 0.83 |
| ▸ | LMNA | P02545 | 8/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | NCOA1 | Q15788 | 3/20 | 0.59 |
| ▸ | NCOA3 | Q9Y6Q9 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15056713 | 0.96 | HTT (0.81) | HTTCCNCCDK8LMNAMAPT | |
| SCHEMBL4359487 | 0.91 | HTT (1.00) | HTTCCNCCDK8LMNAMAPT | |
| SCHEMBL13283258 | 0.85 | LMNA (0.83) | HTTCCNCCDK8LMNAMAPT | |
| SCHEMBL13283182 | 0.85 | HTT (0.69) | HTTCCNCCDK8LMNAMAPT | |
| SCHEMBL14300930 | 0.85 | LMNA (0.76) | HTTCCNCCDK8LMNAMAPT | |
| SCHEMBL13283185 | 0.85 | HTT (0.68) | HTTCCNCCDK8LMNAMAPT | |
| SCHEMBL14300973 | 0.84 | HTT (0.59) | HTTCCNCCDK8LMNAMAPT | |
| SCHEMBL14300974 | 0.83 | HTT (0.75) | HTTCCNCCDK8LMNAMAPT | |
| SCHEMBL13874409 | 0.82 | HTT (0.73) | HTTCCNCCDK8LMNAMAPT | |
| SCHEMBL5076850 | 0.82 | LMNA (1.00) | HTTCCNCCDK8LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-11-19 | — | — | US | claimed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9259426-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20100190807-A1 | CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein | SENEX BIOTECHNOLOGY, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090281129-A1 | CDKI PATHWAY INHIBITORS AND USES THEREOF | SENEX BIOTECHNOLOGY, INC. | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | HTT 2808/4885CCNC 1372/4885CDK8 781/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | HTT 2808/4885CCNC 1372/4885CDK8 781/4885 |
| US-20100190807-A1 | CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein | MAPT, CDK5, CDKN1A | HTT 292/4885CCNC 89/4885CDK8 13/4885 |
| US-20090281129-A1 | CDKI PATHWAY INHIBITORS AND USES THEREOF | CDKN1A, CDK6, CCNI | HTT 930/4885CCNC 32/4885CDK8 9/4885 |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR5A2, NR4A1 | HTT 2522/4885CCNC 1318/4885CDK8 520/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | HTT 2545/4885CCNC 1191/4885CDK8 441/4885 |
| US-20160257673-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR5A2 | HTT 2545/4885CCNC 1191/4885CDK8 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.